<DOC>
	<DOCNO>NCT01396057</DOCNO>
	<brief_summary>This clinical trial design compare ranibizumab comparison Dexamethasone implant 6 month treatment . In study arm Ranibizumab give monthly pro nata scheme whereas comparator Dexamethasone implant give Month 0 sham injection PRN afterwards .</brief_summary>
	<brief_title>Efficacy Safety Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant Patients With Branch Retinal Vein Occlusion ( BRVO )</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Patients diagnose visual impairment due macular edema follow BRVO Diagnosis BRVO maximum 6 month prior Screening BCVA use ETDRS chart 20/40 20/400 study eye Media clarity , pupillary dilation patient cooperation sufficient adequate fundus photographs Central retinal thickness ( CRT ) &lt; 250 µm study eye Prior episode RVO study eye Active formation new vessel study eye AntiVEGFtreatment study fellow eye 3 month prior Baseline IOP ≥ 30mmHg uncontrolled glaucoma ; patient may rescreened 1 month undergone glaucoma treatment Improvement &gt; 10 letter BCVA Screening Baseline Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Visual impairment</keyword>
	<keyword>macular edema</keyword>
	<keyword>branch retinal vein occlusion</keyword>
	<keyword>Dexamethasone implant</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>